Last reviewed · How we verify

Placebo to ezetimibe/atorvastatin

Organon and Co · Phase 3 active Small molecule

Placebo to ezetimibe/atorvastatin is a Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Hyperlipidemia, Homozygous familial hypercholesterolemia.

Ezetimibe inhibits the absorption of cholesterol in the small intestine, while atorvastatin inhibits HMG-CoA reductase to reduce cholesterol production in the liver.

Ezetimibe inhibits the absorption of cholesterol in the small intestine, while atorvastatin inhibits HMG-CoA reductase to reduce cholesterol production in the liver. Used for Hyperlipidemia, Homozygous familial hypercholesterolemia.

At a glance

Generic namePlacebo to ezetimibe/atorvastatin
SponsorOrganon and Co
Drug classCholesterol absorption inhibitor/HMG-CoA reductase inhibitor
TargetNPC1L1/HMG-CoA reductase
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Ezetimibe works by binding to the Niemann-Pick C1-like 1 (NPC1L1) protein on intestinal cells, preventing the absorption of cholesterol from the diet. Atorvastatin, on the other hand, inhibits the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By reducing both dietary and endogenous cholesterol, ezetimibe/atorvastatin helps to lower LDL cholesterol levels in the blood.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to ezetimibe/atorvastatin

What is Placebo to ezetimibe/atorvastatin?

Placebo to ezetimibe/atorvastatin is a Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor drug developed by Organon and Co, indicated for Hyperlipidemia, Homozygous familial hypercholesterolemia.

How does Placebo to ezetimibe/atorvastatin work?

Ezetimibe inhibits the absorption of cholesterol in the small intestine, while atorvastatin inhibits HMG-CoA reductase to reduce cholesterol production in the liver.

What is Placebo to ezetimibe/atorvastatin used for?

Placebo to ezetimibe/atorvastatin is indicated for Hyperlipidemia, Homozygous familial hypercholesterolemia.

Who makes Placebo to ezetimibe/atorvastatin?

Placebo to ezetimibe/atorvastatin is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

What drug class is Placebo to ezetimibe/atorvastatin in?

Placebo to ezetimibe/atorvastatin belongs to the Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor class. See all Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor drugs at /class/cholesterol-absorption-inhibitor-hmg-coa-reductase-inhibitor.

What development phase is Placebo to ezetimibe/atorvastatin in?

Placebo to ezetimibe/atorvastatin is in Phase 3.

What are the side effects of Placebo to ezetimibe/atorvastatin?

Common side effects of Placebo to ezetimibe/atorvastatin include Musculoskeletal pain, Liver enzyme elevation, Diarrhea.

What does Placebo to ezetimibe/atorvastatin target?

Placebo to ezetimibe/atorvastatin targets NPC1L1/HMG-CoA reductase and is a Cholesterol absorption inhibitor/HMG-CoA reductase inhibitor.

Related